Akoyabio
Billerica, US · Founded 2015 · 2 known investors
Akoya (part of Quanterix) develops biomarker detection platforms combining liquid Simoa immunoassays for blood and CSF with spatial tissue proteomics, providing matched biomarker insights across matrices. It serves pharmaceutical companies, CROs, diagnostics labs, and researchers in fields such as neurology, oncology, immunology, cardiology, and infectious disease.
BiotechHealthtechMedical Devices
Founders & leadership
GN
Garry NolanDirector
TR
Thomas RaffinDirector
MW
Matthew WinklerDirector
BM
Brian McKelligonExecutive Officer
RH
Rob HartExecutive Officer
RS
Robert SheplerDirector
Investors · 2
Reported raises · per SEC filings
Form D private placements▶$24.5MraisedOct 2018 · 6 investors · OtherRule 506(b)
▶$24.5MraisedOct 2018 · 6 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Garry NolanDirector
- Thomas RaffinDirector
- Matthew WinklerDirector
- Brian McKelligonExecutive Officer, Director
- Robert SheplerDirector
- Rob HartExecutive Officer
- Offering amount
- $25.5M
- Amount sold
- $24.5M
- First sale
- Sep 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$9MraisedJul 2017 · 6 investors · OtherRule 506(b)
▶$9MraisedJul 2017 · 6 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Garry NolanDirector
- Rob HartExecutive Officer
- Robert SheplerDirector
- Thomas RaffinDirector
- Matthew WinklerDirector
- Brian McKelligonExecutive Officer
- Offering amount
- $9M
- Amount sold
- $9M
- First sale
- Jul 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $149.6K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.